Why the study?
Does ETA receptor blockade with LU-135252, alone or combined with RAS inhibition, reduce mean arterial pressure in normotensive dogs?
Does ETA receptor blockade with LU-135252, alone or combined with RAS inhibition, reduce mean arterial pressure in normotensive dogs?
Endothelin-1 contributes to blood pressure maintenance via ETA receptors, and combined ETA and RAS blockade synergistically reduces blood pressure, likely mediated by enhanced nitric oxide release.
Answers are grounded in this paper and cite their sources.
Combined ETA/RAS blockade synergistically lowers MAP in normotensive dogs; leaves open translation to hypertensive models or patients.
The role of endothelin (ET)-1 in blood pressure homeostasis and the interaction with the renin-angiotensin system (RAS) was investigated in normotensive conscious dogs. ETA receptors were blocked by LU-135252 (1-30 mg/kg); trandolapril (2 mg/kg) or losartan (10 mg/kg) was used to inhibit the RAS. LU-135252 in oral doses of 3-30 mg/kg significantly reduced mean arterial pressure (MAP) by approximately 10 mmHg maximally, whereas trandolapril or losartan were without any effect. MAP reduction was more pronounced when LU-135252 was combined with either losartan (-15.5 +/- 3.2 mmHg; 2 h postadministration; P < 0.05) or trandolapril (-30.9 +/- 3.6 mmHg; P < 0.05). When endogenous nitric oxide (NO) generation was blocked but NO concomitantly infused, this synergistic effect on MAP was prevented. The data show that ET-1 contributes to the maintenance of blood pressure via ETA receptors. Furthermore, ET-1 and ANG II play a prominent role in the control of blood pressure by opposing the effects of NO. The pronounced blood pressure fall after combined blockade of ETA receptors and the RAS may be mediated by an enhanced release of NO.
No takes yet. Share an insight, caveat, or question.
Münter et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: